期刊
CANCER LETTERS
卷 352, 期 2, 页码 245-252出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.07.004
关键词
Hepatitis B virus; Hepatocellular carcinoma; Sorafenib; Myeloid cell leukemia-1; MiR-193b; Apoptosis
类别
资金
- National Natural Science Foundation of China [81201921, 81372565, 81302161]
- Doctoral Fund of Ministry of Education of China [20120171110076]
- Techpool Bio-pharma Co., Ltd (Guangzhou, China)
Background: Chronic infection with Hepatitis B virus (HBV) is the major risk factor of Hepatocellular Carcinoma (HCC). This study is to explore the mechanism of sorafenib resistance and find an effective strategy to sensitize HBV-associated HCC to sorafenib. Methods: Cytotoxicity to sorafenib was evaluated in HBV-positive/negative HCC cell lines. Expression of miR-193b and myeloid cell leukemia-1 (Mcl-1) protein were assessed by Q-PCR, in situ hybridization and western blot, immunohistochemistry, respectively. A luciferase reporter of Mcl-1 3'-UTR was used for validation as a target of miR-193b. Cell apoptosis was measured by flow cytometry, caspase-3 activity assay and DAPI staining. Result: The IC50 to sorafenib was significantly higher in HBV-positive HCC cells than those without HBV infection. Significant downregulation of miR-193b and a higher level of Mcl-1 were observed in HBV-positive HCC cells and tissues. The activity of Mcl-1 3'-UTR reporter was inhibited by co-transfection with miR-193b mimic. Restoring the expression of miR-193b sensitized HBV-associated HCC cells to sorafenib treatment and facilitated sorafenib-induced apoptosis. Conclusions: Modulation of miRNAs expression might be a potential way to enhance response to sorafenib in HBV-associated HCC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据